Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

CEACAM5 (CEA Cell Adhesion Molecule 5)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

Mammostrat® Breast Cancer Recurrence Assay

Mammostrat® Breast Cancer Recurrence Assay

›

CEACAM5 positive	Gastric Cancer	CEACAM5 positive	Gastric Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 positive	Lung Cancer	CEACAM5 positive	Lung Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 positive	Colorectal Cancer	CEACAM5 positive	Colorectal Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 expression	Lung Non-Squamous Non-Small Cell Cancer	CEACAM5 expression	Lung Non-Squamous Non-Small Cell Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 expression	Gastric Cancer	CEACAM5 expression	Gastric Cancer	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 expression	Solid Tumor	CEACAM5 expression	Solid Tumor	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2	SAR408701 Sensitive: C2 – Inclusion Criteria SAR408701 Sensitive : C2
CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	SAR408701 Sensitive: C3 – Early Trials SAR408701 Sensitive : C3	SAR408701 Sensitive: C3 – Early Trials SAR408701 Sensitive : C3
CEACAM5 overexpression	Gastric Cancer	CEACAM5 overexpression	Gastric Cancer	SAR408701 Sensitive: C3 – Early Trials SAR408701 Sensitive : C3	SAR408701 Sensitive: C3 – Early Trials SAR408701 Sensitive : C3
CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab + SAR408701 Sensitive: C3 – Early Trials pembrolizumab + SAR408701 Sensitive : C3	pembrolizumab + SAR408701 Sensitive: C3 – Early Trials pembrolizumab + SAR408701 Sensitive : C3
CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	CEACAM5 overexpression	Lung Non-Squamous Non-Small Cell Cancer	ramucirumab + SAR408701 Sensitive: C3 – Early Trials ramucirumab + SAR408701 Sensitive : C3	ramucirumab + SAR408701 Sensitive: C3 – Early Trials ramucirumab + SAR408701 Sensitive : C3